ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06218251
- Locations
- ๐บ๐ธ
Skin Wellness Dermatology - Homewood /ID# 248469, Birmingham, Alabama, United States
๐บ๐ธThe Research Center at The Maas Clinic /ID# 256633, San Francisco, California, United States
๐บ๐ธPacific Clinical Innovations /ID# 248467, Vista, California, United States
A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT06174688
- Locations
- ๐จ๐ณ
Peking University First Hospital /ID# 249912, Xicheng District, Beijing, China
๐จ๐ณWest China Hospital, Sichuan University /ID# 250474, Chengdu, Sichuan, China
๐จ๐ณBeijing Hospital /ID# 250059, Beijing, Beijing, China
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 76
- Registration Number
- NCT06158854
- Locations
- ๐ฎ๐น
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 255654, Bologna, Emilia-Romagna, Italy
๐บ๐ธSylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida, United States
๐บ๐ธBoston Medical Center /ID# 255066, Boston, Massachusetts, United States
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- ๐จ๐ณ
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
๐บ๐ธAlta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
๐บ๐ธProvidence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 192
- Registration Number
- NCT06158958
- Locations
- ๐บ๐ธ
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943, New York, New York, United States
๐บ๐ธCity of Hope /ID# 254303, Duarte, California, United States
๐บ๐ธCity of Hope at Orange County Lennar Foundation Cancer Center /ID# 266792, Irvine, California, United States
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT06151561
- Locations
- ๐ฏ๐ต
Tokyo Center Clinic /ID# 257898, Central District, Tokyo, Japan
A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT06151535
- Locations
- ๐ฎ๐น
CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 226370, Verona, Italy
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
- Conditions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 107
- Registration Number
- NCT06150729
- Locations
- ๐ฒ๐ฝ
Hospital General ISSSTE Tacuba /ID# 261460, Ciudad de Mรฉxico, Ciudad De Mexico, Mexico
๐ฒ๐ฝCri Dif Jalisco /Id# 261459, Guadalajara, Mexico
๐ฒ๐ฝHospital General Regional 180 IMSS /ID# 261458, Guadalajara, Jalisco, Mexico
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 99
- Registration Number
- NCT06148181
- Locations
- ๐บ๐ธ
Acpru /Id# 261162, Grayslake, Illinois, United States
A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 259
- Registration Number
- NCT06137287
- Locations
- ๐ฏ๐ต
Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 260668, Sapporo, Hokkaido, Japan
๐ฏ๐ตTokai University Hospital /ID# 254204, Isehara, Kanagawa, Japan
๐ฏ๐ตJun Clinic /Id# 254870, Nagano, Fukui, Japan